Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia

키워드

참고문헌 (92)

1. Tsao CW, "Heart disease and stroke statistics-2022 update : a report from the American Heart Association", Circulation, 145, pp.e153~e639 (2022)
2. Hyeok-Hee Lee, "Korea Heart Disease Fact Sheet 2020: Analysis of Nationwide Data", Korean Circulation Journal, 51(6), pp.495~503 (2021), 대한심장학회[DOI]
3. Pirillo A, "Global epidemiology of dyslipidaemias", Nat Rev Cardiol, 18, pp.689~700 (2021)
4. 조소미, "Dyslipidemia Fact Sheets in Korea 2020: an Analysis of Nationwide Population-based Data", 지질·동맥경화학회지, 10(2), pp.202~209 (2021), 한국지질동맥경화학회[DOI]
5. Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
6. Writing Committee, "2022 ACC expert consensus decision pathway for integrating atherosclerotic cardiovascular disease and multimorbidity treatment : a framework for pragmatic, patient-centered care : a report of the American College of Cardiology Solution Set Oversight Committee", J Am Coll Cardiol, 81, pp.292~317 (2023)
7. Pearson GJ, "2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults", Can J Cardiol, 37, pp.1129~1150 (2021)
8. Visseren FLJ, "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice", Eur Heart J, 42, pp.3227~3337 (2021)
9. Borén J, "Low-density lipoproteins cause atherosclerotic cardiovascular disease : pathophysiological, genetic, and therapeutic insights : a consensus statement from the European Atherosclerosis Society Consensus Panel", Eur Heart J, 41, pp.2313~2330 (2020)
10. Kunutsor SK, "Further proof of a paradoxical relationship between high-density lipoprotein levels and adverse cardiovascular outcomes : are there implications for cardiovascular disease prevention?", Eur J Prev Cardiol, 30, pp.290~292 (2023)
11. 이은정, "2018 Guidelines for the Management of Dyslipidemia in Korea", 지질·동맥경화학회지, 8(2), pp.78~131 (2019), 한국지질동맥경화학회[DOI]
12. 이상학, "Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea", 지질·동맥경화학회지, 8(2), pp.242~251 (2019), 한국지질동맥경화학회[DOI]
13. 양여리, "High-Density Lipoprotein Cholesterol and the Risk of Myocardial Infarction, Stroke, and Cause-Specific Mortality: a Nationwide Cohort Study in Korea", 지질·동맥경화학회지, 10(1), pp.74~87 (2021), 한국지질동맥경화학회[DOI]
14. 홍승표, "The Comparison of the Associations of Lipoprotein(a) and the Atherogenic Index of Plasma With Coronary Artery Calcification in Patients Without High LDL-C: A Comparative Analysis", 지질·동맥경화학회지, 12(2), pp.152~163 (2023), 한국지질동맥경화학회[DOI]
15. 김경안, "New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)", 지질·동맥경화학회지, 12(1), pp.37~46 (2023), 한국지질동맥경화학회[DOI]
16. Kim Kihyun, "Comparison of the Effects of Highintensity Statin Therapy with Moderate-Intensity Statin and Ezetimibe Combination Therapy on Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction: a Nationwide Cohort Study", 지질·동맥경화학회지, 10(3), pp.291~302 (2021), 한국지질동맥경화학회[DOI]
17. Grundy SM, "2018 American Heart Association", American College of Cardiology, JAMA Cardiol, pp.2019, 4[DOI]
18. Mach F, "2019 ESC", EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, 2020, pp.41, 111~188
19. Handelsman Y, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary", Endocr Pract, 26, pp.1196~1224 (2020)
20. Newman CB, "Lipid management in patients with endocrine disorders : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 105, pp.dgaa674~ (2020)
21. Sweeney ME, "Ezetimibe : an update on the mechanism of action, pharmacokinetics and recent clinical trials", Expert Opin Drug Metab Toxicol, 3, pp.441~450 (2007)
22. Zhang DW, "Binding of proprotein convertase subtilisin", kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, 2007, pp.282, 18602~18612
23. Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
24. Sabatine MS, "Evolocumab and clinical outcomes in patients with cardiovascular disease", N Engl J Med, 376, pp.1713~1722 (2017)
25. Schwartz GG, "Alirocumab and cardiovascular outcomes after acute coronary syndrome", N Engl J Med, 379, pp.2097~2107 (2018)
26. Schwartz GG, "Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction:the ODYSSEY OUTCOMES trial", Eur Heart J, 44, pp.1408~1417 (2023)
27. Pandor A, "Ezetimibe monotherapy for cholesterol lowering in 2, 722 people : systematic review and meta-analysis of randomized controlled trials", J Intern Med, 265, pp.568~580 (2009)
28. Bytyçi I, "Prevalence of statin intolerance : a meta-analysis", Eur Heart J, 43, pp.3213~3223 (2022)
29. Ara R, "Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications : a Markov model", Am J Cardiovasc Drugs, 8, pp.419~427 (2008)
30. Nissen SE, "Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3randomized clinical trial", JAMA, 315, pp.1580~1590 (2016)
31. Ouchi Y, "Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75or older(EWTOPIA 75) : a randomized, controlled trial", Circulation, 140, pp.992~1003 (2019)
32. Maxfield FR, "Role of cholesterol and lipid organization in disease", Nature, 438, pp.612~621 (2005)
33. Duan Y, "Regulation of cholesterol homeostasis in health and diseases : from mechanisms to targeted therapeutics", Signal Transduct Target Ther, 7, pp.265~ (2022)
34. Lee J, "Effect of ezetimibe added to high-intensity statin therapy on low-density lipoprotein cholesterol levels : a meta-analysis", Cardiol Res, 12, pp.98~108 (2021)
35. Gudzune KA, "Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy : a systematic review", Ann Intern Med, 160, pp.468~476 (2014)
36. Toth PP, "Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol", J Am Heart Assoc, 11, pp.e025551~ (2022)
37. Baigent C, "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial", Lancet, 377, pp.2181~2192 (2011)
38. Kouvelos GN, "Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery : results of a pilot study", J Cardiovasc Pharmacol Ther, 18, pp.5~12 (2013)
39. Wang X, "Effects of combination of ezetimibe and rosuvastatin on coronary artery plaque in patients with coronary heart disease", Heart Lung Circ, 25, pp.459~465 (2016)
40. Hagiwara N, "Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia : the HIJ-PROPER study, a prospective, open-label, randomized trial", Eur Heart J, 38, pp.2264~2276 (2017)
41. Liu Z, "Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome", Oncotarget, 8, pp.41582~41589 (2017)
42. Hibi K, "Effects of ezetimibe-statin combination therapy on coronary atherosclerosis in acute coronary syndrome", Circ J, 82, pp.757~766 (2018)
43. Ogiso M, "Effect of aggressive lipid-lowering therapy in single-vessel vs. multivessel coronary artery disease patients with acute coronary syndrome　-Heart Institute of Japan-Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome(HIJ-PROPER)Substudy", Circ Rep, 2, pp.128~134 (2020)
44. Kim BK, "Longterm efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial", Lancet, 400, pp.380~390 (2022)
45. Zhan S, "Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events", Cochrane Database Syst Rev, 11, pp.CD012502~ (2018)
46. Bernardi S, "The complex interplay between lipids, immune system and interleukins in cardio-metabolic diseases", Int J Mol Sci, 19, pp.4058~ (2018)
47. Kastelein JJ, "Simvastatin with or without ezetimibe in familial hypercholesterolemia", N Engl J Med, 358, pp.1431~1443 (2008)
48. Howard BV, "Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes : the SANDS randomized trial", JAMA, 299, pp.1678~1689 (2008)
49. Meaney A, "The VYtorin on Carotid intima-media thickness and overall arterial rigidity(VYCTOR)study", J Clin Pharmacol, 49, pp.838~847 (2009)
50. Tsujita K, "Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial", J Am Coll Cardiol, 66, pp.495~507 (2015)
51. Hougaard M, "Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial : Intravascular ultrasound with iMap : the OCTIVUS trial", Cardiovasc Revasc Med, 18, pp.110~117 (2017)
52. Newby AC, "Dual role of matrix metalloproteinases(matrixins)in intimal thickening and atherosclerotic plaque rupture", Physiol Rev, 85, pp.1~31 (2005)
53. Tan H, "Effects of combined lipid-lowering therapy on low-density lipoprotein cholesterol variability and cardiovascular adverse events in patients with acute coronary syndrome", Adv Ther, 38, pp.3389~3398 (2021)
54. Wolf D, "Immunity and Inflammation in Atherosclerosis", Circ Res, 124, pp.315~327 (2019)
55. Ridker PM, "A test in context : high-sensitivity C-reactive protein", J Am Coll Cardiol, 67, pp.712~723 (2016)
56. Luo P, "Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia", Genet Mol Res, 13, pp.2377~2384 (2014)
57. Ren Y, "Comparison of the effect of rosuvastatin versus rosuvastatin", ezetimibe on markers of inflammation in patients with acute myocardial infarction, 2017, pp.14, 4942~4950
58. Wang J, "Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease", Int Angiol, 36, pp.467~473 (2017)
59. Yang W, "Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials", Medicine(Baltimore), 101, pp.e30563~ (2022)
60. Cho Y, "Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue", Biomedicines, 8, pp.512~ (2020)
61. Sun C, "Ezetimibe improves rosuvastatin effects on inflammation and vascular endothelial function in acute coronary syndrome patients undergoing PCI", J Interv Cardiol, 2021, pp.2995602~ (2021)
62. Krysiak R, "The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia", Cardiovasc Ther, 32, pp.40~46 (2014)
63. Mostafa Arabi S, "The effect of combination therapy with statins and ezetimibe on proinflammatory cytokines : a systematic review and meta-analysis of randomized controlled trials", Int Immunopharmacol, 113(Pt B), pp.109477~ (2022)
64. Hussein O, "Ezetimibe’s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin", Br J Clin Pharmacol, 65, pp.637~645 (2008)
65. Pesaro AE, "Pleiotropic effects of ezetimibe", simvastatin vs. high dose simvastatin, 2012, pp.158, 400~404
66. Moutzouri E, "Comparison of the effect of simvastatin versus simvastatin", ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia, 2013, pp.231, 8~14
67. Sakuma M, "Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia", Hypertens Res, 42, pp.1923~1931 (2019)
68. Takase S, "Ezetimibe in combination with statins ameliorates endothelial dysfunction in coronary arteries after stenting : the CuVIC trial(effect of cholesterol absorption inhibitor usage on target vessel dysfunction after coronary stenting), a multicenter randomized controlled trial", Arterioscler Thromb Vasc Biol, 37, pp.350~358 (2017)
69. Ridker PM, "Cardiovascular benefits and diabetes risks of statin therapy in primary prevention : an analysis from the JUPITER trial", Lancet, 380, pp.565~571 (2012)
70. Cederberg H, "Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion : a 6 year follow-up study of the METSIM cohort", Diabetologia, 58, pp.1109~1117 (2015)
71. Agarwala A, "The association of statin therapy with incident diabetes : evidence, mechanisms, and recommendations", Curr Cardiol Rep, 20, pp.50~ (2018)
72. Betteridge DJ, "The diabetogenic action of statins-mechanisms and clinical implications", Nat Rev Endocrinol, 12, pp.99~110 (2016)
73. Her AY, "Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin", ezetimibe 5 mg, J Cardiovasc Pharmacol Ther, pp.2010, 15[DOI]
74. Adachi H, "Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia", Lipids Health Dis, 14, pp.1~ (2015)
75. Ohbu-Murayama K, "Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome", J Diabetes Investig, 6, pp.325~333 (2015)
76. Takeshita Y, "The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism : a randomised controlled trial", Diabetologia, 57, pp.878~890 (2014)
77. Zhong Y, "Effect of ezetimibe on insulin secretion in db", db diabetic mice, 2012, pp.2012, 420854~
78. Zeng KY, "Non-invasive evaluation of liver steatosis with imaging modalities : new techniques and applications", World J Gastroenterol, 29, pp.2534~2550 (2023)
79. Kim SH, "Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition", Autophagy, 13, pp.1767~1781 (2017)
80. Park H, "Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.101~107 (2011)
81. Simon TG, "The nonalcoholic fatty liver disease(NAFLD)fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe", Int J Cardiol, 270, pp.245~252 (2018)
82. 이효영, "Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis", The Korean Journal of Internal Medicine, 34(2), pp.296~304 (2019), 대한내과학회[DOI]
83. Cho Y, "Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease : an open-label randomized controlled trial(ESSENTIAL study)", BMC Med, 20, pp.93~ (2022)
84. Stroes ES, "Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management", Eur Heart J, 36, pp.1012~1022 (2015)
85. Cha JJ, "Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease : Rationale and design of a randomized, controlled SaveSAMS trial", Am Heart J, 261, pp.45~50 (2023)
86. Davidson MH, "Striated muscle safety of ezetimibe", simvastatin(Vytorin), 2006, pp.97, 223~228
87. Lee YJ, "Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial", Eur Heart J, 44, pp.972~983 (2023)
88. Dujovne CA, "Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia", Am J Cardiol, 90, pp.1092~1097 (2002)
89. Phillips PS, "Ezetimibe and statin-associated myopathy", Ann Intern Med, 141, pp.649~ (2004)
90. Fux R, "Ezetimibe and statin-associated myopathy", Ann Intern Med, 140, pp.671~672 (2004)
91. Nutescu EA, "Ezetimibe : a selective cholesterol absorption inhibitor", Pharmacotherapy, 23, pp.1463~1474 (2003)
92. Newman CB, "Safety of statins and nonstatins for treatment of dyslipidemia", Endocrinol Metab Clin North Am, 51, pp.655~679 (2022)

관련 논문AI추천